GMRE:NYE-Global Medical REIT Inc (USD)

COMMON STOCK | REIT - Healthcare Facilities |

Last Closing

USD 9.4

Change

-0.04 (-0.42)%

Market Cap

N/A

Volume

0.30M

Analyst Target

USD 14.79
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-07 )

Largest Industry Peers for REIT - Healthcare Facilities

Symbol Name Price(Change) Market Cap
WELL Welltower Inc

-1.29 (-1.03%)

USD 77.48B
VTR Ventas Inc

+0.09 (+0.14%)

USD 25.93B
DOC Healthpeak Properties Inc

-0.11 (-0.50%)

USD 15.46B
CTRE CareTrust REIT Inc.

+0.12 (+0.40%)

USD 4.68B
AHR American Healthcare REIT, Inc.

-0.11 (-0.44%)

USD 3.83B
NHI National Health Investors Inc

-0.52 (-0.64%)

USD 3.53B
LTC LTC Properties Inc

+0.27 (+0.75%)

USD 1.57B
UHT Universal Health Realty Income..

-0.74 (-1.71%)

USD 0.63B
CHCT Community Healthcare Trust Inc

-0.05 (-0.29%)

USD 0.48B
GMRE-PA Global Medical REIT Inc

+0.07 (+0.27%)

USD 0.41B

ETFs Containing GMRE

KBWY Invesco KBW Premium Yield.. 5.12 % 0.35 %

-0.11 (0%)

USD 0.25B
SDEF 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (REIT - Healthcare Facilities) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.32% 14% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.32% 14% F 19% F
Trailing 12 Months  
Capital Gain 6.94% 29% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.94% 29% F 36% F
Trailing 5 Years  
Capital Gain -18.97% 46% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.97% 46% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike